Ligufalimab clinical trials
Also written AK117.
How each study uses ligufalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ligufalimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
14 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 3
Akeso (10) · West China Hospital (1) · Akesobio Australia Pty Ltd (1) · Groupe Oncologie Radiotherapie Tete et Cou (1) · University of Texas Southwestern Medical Center (1)
Often tested with
Tested in the same studies.
Ivonescimab (5) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Gemcitabine (1) · Cadonilimab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test ligufalimab, phase 3 first.
- Jan 2027A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)Phase 3 · Akeso
- May 2027A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerPhase 3 · Akeso
- Dec 2026A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerPhase 2 · Akeso
Studies
Open first, then newest update. How each study uses ligufalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHNRecruitingPhase 3Groupe Oncologie Radiotherapie Tete et CouNCT07264075Written as Ligufalimab
- A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerRecruitingPhase 3AkesoNCT06953999Written as Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine
- Ligufalimab and Cadonilimab in Advanced Liver CancersRecruitingPhase 2University of Texas Southwestern Medical CenterNCT06789848Written as Ligufalimab
- A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic SyndromesRecruitingPhase 2AkesoNCT06196203Written as AK117
- A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)RecruitingPhase 3AkesoNCT06601335Written as AK117 in combination with AK112
- A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid LeukemiaNot yet recruitingPhase 1/2AkesoNCT06387420Written as AK117
- Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2AkesoNCT05960955Written as AK117
- AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedPhase 2West China HospitalNCT06508606Written as AK117 + Cetuximab
- A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerActive, not recruitingPhase 2AkesoNCT05227664Written as AK117
- A Study of AK112 in Advanced Malignant TumorsCompletedPhase 1/2AkesoNCT05214482Written as AK117
- A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic SyndromeActive, not recruitingPhase 1/2AkesoNCT04900350Written as AK117
- A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid LeukemiaActive, not recruitingPhase 1/2AkesoNCT04980885Written as AK117
- A Phase 1 Dose Escalation and Expansion Study of AK117CompletedPhase 1AkesoNCT04728334Written as AK117
- A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104CompletedPhase 1Akesobio Australia Pty LtdNCT04349969Written as AK117
Given beside what is tested · 5 — ligufalimab is usual care or a partner of the new treatment
- A Study of Ivonescimab in First-Line ES-SCLCRecruitingPhase 2AkesoNCT07245446Written as AK117
- A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaRecruitingPhase 1/2AkesoNCT06642792Written as AK117
- A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant TumorsCompletedPhase 1/2AkesoNCT05235542Written as AK117
- A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant TumorsActive, not recruitingPhase 1/2AkesoNCT05229497Written as AK117
- A Study of AK112 With or Without AK117 in Metastatic Colorectal CancerActive, not recruitingPhase 2AkesoNCT05382442Written as AK117
Codes
What other systems call ligufalimab · ClinicalTrials.gg INT014347
- UNII (FDA) 1S4338NZB8LIGUFALIMABOne source FDA
- NCI Thesaurus C176868LigufalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1S4338NZB8 | LIGUFALIMAB | One source FDA |
| NCI Thesaurus | C176868 | Ligufalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.